#read

Vita 34 returns to growth path in 2023

Vita 34 AG, Europe's leading cell bank, recorded significant business development in the 2023 financial year and increased its consolidated revenue by 11.8 per cent to EUR 77.1 million.

30/04/2024

Despite a difficult environment with declining birth rates, the company was able to grow, particularly in Hungary, Switzerland, Romania and Turkey. Despite extraordinary one-off effects totalling 1.5 million euros, EBITDA improved to 5.6 million euros. The operating cash flow almost tripled to 9.2 million euros.

Jakub Baran, CEO of Vita 34 AG, emphasised the successful adaptation to the difficult economic environment and the contribution of consistent cost and liquidity management. Investments in cell and gene therapies will continue to be financed from the existing liquidity and ongoing projects.

For 2024, Vita 34 plans to further strengthen organic growth and expects revenues of between EUR 81 and 88 million and EBITDA of between EUR 6.5 and 8.0 million. Investments in marketing and sales are expected to show significant effects in the second half of the year.

Article from "Vita34" from 30 April 2024

The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.

Click here to access the original content